These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 16914310)
21. Advances in the biology and treatment of oligodendrogliomas. van den Bent MJ Curr Opin Neurol; 2004 Dec; 17(6):675-80. PubMed ID: 15542975 [TBL] [Abstract][Full Text] [Related]
22. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413 [TBL] [Abstract][Full Text] [Related]
23. A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Gan HK; Rosenthal MA; Dowling A; Kalnins R; Algar E; Wong N; Benson A; Woods AM; Cher L Neuro Oncol; 2010 May; 12(5):500-7. PubMed ID: 20406900 [TBL] [Abstract][Full Text] [Related]
24. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. van den Bent MJ; Taphoorn MJ; Brandes AA; Menten J; Stupp R; Frenay M; Chinot O; Kros JM; van der Rijt CC; Vecht ChJ; Allgeier A; Gorlia T; J Clin Oncol; 2003 Jul; 21(13):2525-8. PubMed ID: 12829671 [TBL] [Abstract][Full Text] [Related]
25. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. ; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910 [TBL] [Abstract][Full Text] [Related]
26. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. Chahlavi A; Kanner A; Peereboom D; Staugaitis SM; Elson P; Barnett G J Neurooncol; 2003 Feb; 61(3):267-73. PubMed ID: 12675321 [TBL] [Abstract][Full Text] [Related]
27. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Giannini C; Burger PC; Berkey BA; Cairncross JG; Jenkins RB; Mehta M; Curran WJ; Aldape K Brain Pathol; 2008 Jul; 18(3):360-9. PubMed ID: 18371182 [TBL] [Abstract][Full Text] [Related]
28. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A; Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167 [TBL] [Abstract][Full Text] [Related]
30. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179 [TBL] [Abstract][Full Text] [Related]
31. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879 [TBL] [Abstract][Full Text] [Related]
32. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966 [TBL] [Abstract][Full Text] [Related]
33. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682 [TBL] [Abstract][Full Text] [Related]
34. Fluorescence in situ hybridization for 1p, 19q status in a cohort of glial neoplasms. Singh VY; Chacko G; Chacko AG; Rajshekhar V Neurol India; 2014; 62(1):32-6. PubMed ID: 24608451 [TBL] [Abstract][Full Text] [Related]
35. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide. Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755 [TBL] [Abstract][Full Text] [Related]
36. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Vogelbaum MA; Berkey B; Peereboom D; Macdonald D; Giannini C; Suh JH; Jenkins R; Herman J; Brown P; Blumenthal DT; Biggs C; Schultz C; Mehta M Neuro Oncol; 2009 Apr; 11(2):167-75. PubMed ID: 18779504 [TBL] [Abstract][Full Text] [Related]
38. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Jenkins RB; Curran W; Scott CB; Cairncross G Am J Clin Oncol; 2001 Oct; 24(5):506-8. PubMed ID: 11586105 [TBL] [Abstract][Full Text] [Related]
39. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment? Ramirez C; Bowman C; Maurage CA; Dubois F; Blond S; Porchet N; Escande F Neuro Oncol; 2010 May; 12(5):490-9. PubMed ID: 20156805 [TBL] [Abstract][Full Text] [Related]
40. Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment. Higuchi F; Uzuka T; Matsuda H; Sumi T; Iwata K; Namatame T; Shin M; Akutsu H; Ueki K Brain Tumor Pathol; 2024 Apr; 41(2):80-84. PubMed ID: 38294664 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]